用于分析优先结果的加权胜负方法。
Weighted win loss approach for analyzing prioritized outcomes.
作者信息
Luo Xiaodong, Qiu Junshan, Bai Steven, Tian Hong
机构信息
Research and Development, Sanofi US, Bridgewater, 08807, NJ, U.S.A.
Division of Biometrics I, Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, U.S.A.
出版信息
Stat Med. 2017 Jul 10;36(15):2452-2465. doi: 10.1002/sim.7284. Epub 2017 Mar 26.
Abstract
To analyze prioritized outcomes, Buyse (2010) and Pocock et al. (2012) proposed the win loss approach. In this paper, we first study the relationship between the win loss approach and the traditional survival analysis on the time to the first event. We then propose the weighted win loss statistics to improve the efficiency of the unweighted methods. A closed-form variance estimator of the weighted win loss statistics is derived to facilitate hypothesis testing and study design. We also calculated the contribution index to better interpret the results of the weighted win loss approach. Simulation studies and real data analysis demonstrated the characteristics of the proposed statistics. Copyright © 2017 John Wiley & Sons, Ltd.
摘要
为了分析优先结果，比瑟（2010年）和波科克等人（2012年）提出了胜负法。在本文中，我们首先研究胜负法与传统生存分析中首次事件发生时间之间的关系。然后我们提出加权胜负统计量以提高未加权方法的效率。推导了加权胜负统计量的闭式方差估计量，以促进假设检验和研究设计。我们还计算了贡献指数，以便更好地解释加权胜负法的结果。模拟研究和实际数据分析证明了所提出统计量的特性。版权所有© 2017约翰·威利父子有限公司。
相似文献
1
Weighted win loss approach for analyzing prioritized outcomes.用于分析优先结果的加权胜负方法。
Stat Med. 2017 Jul 10;36(15):2452-2465. doi: 10.1002/sim.7284. Epub 2017 Mar 26.
2
An alternative approach to confidence interval estimation for the win ratio statistic.胜率统计量置信区间估计的另一种方法。
Biometrics. 2015 Mar;71(1):139-145. doi: 10.1111/biom.12225. Epub 2014 Aug 25.
3
The stratified win ratio.分层胜率。
J Biopharm Stat. 2018;28(4):778-796. doi: 10.1080/10543406.2017.1397007. Epub 2017 Nov 27.
4
A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components.一种用于分析复合终点的胜率的广义解析解，该解析解考虑了各组成部分之间的临床重要性顺序。
Pharm Stat. 2016 Sep;15(5):430-7. doi: 10.1002/pst.1763. Epub 2016 Aug 2.
5
Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints.用于分析（非）优先复合终点的广义成对比较方法。
Stat Med. 2019 Dec 30;38(30):5641-5656. doi: 10.1002/sim.8388. Epub 2019 Oct 28.
6
The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.胜率：删失和随访时间的影响以及与非比例风险的使用。
Pharm Stat. 2020 May;19(3):168-177. doi: 10.1002/pst.1977. Epub 2019 Oct 31.
7
Efficient estimation of the distribution of time to composite endpoint when some endpoints are only partially observed.当某些终点仅部分可观察到时，复合终点时间分布的有效估计。
Lifetime Data Anal. 2013 Oct;19(4):513-46. doi: 10.1007/s10985-013-9261-9. Epub 2013 May 31.
8
A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial.一种用于重新分析多重危险因素干预试验的胜率方法。
Clin Trials. 2019 Dec;16(6):626-634. doi: 10.1177/1740774519868233. Epub 2019 Aug 7.
9
Introducing a new estimator and test for the weighted all-cause hazard ratio.引入一种新的加权全因风险比估计量和检验方法。
BMC Med Res Methodol. 2019 Jun 11;19(1):118. doi: 10.1186/s12874-019-0765-1.
10
A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien-Wei-Lachin.一种非参数全局优势概率方法在分析和定规模多终点不同尺度和缺失数据的随机对照试验中的应用：超越 O'Brien-Wei-Lachin 方法。
Stat Med. 2024 Dec 10;43(28):5366-5379. doi: 10.1002/sim.10247. Epub 2024 Oct 17.
引用本文的文献
1
The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints.双臂II期临床试验设计中具有多个事件发生时间终点的贝叶斯监测中的胜率方法
Stat Med. 2024 Dec 30;43(30):5922-5934. doi: 10.1002/sim.10282. Epub 2024 Nov 25.
2
Stratified proportional win-fractions regression analysis.分层比例优势分数回归分析。
Stat Med. 2022 Nov 20;41(26):5305-5318. doi: 10.1002/sim.9570. Epub 2022 Sep 14.
3
On recurrent-event win ratio.论再发事件赢率。
Stat Methods Med Res. 2022 Jun;31(6):1120-1134. doi: 10.1177/09622802221084134. Epub 2022 Mar 29.
4
Statistical models for composite endpoints of death and non-fatal events: a review.死亡和非致命事件复合终点的统计模型：综述
Stat Biopharm Res. 2021;13(3):260-269. doi: 10.1080/19466315.2021.1927824. Epub 2021 Jul 6.
5
A class of proportional win-fractions regression models for composite outcomes.一类用于复合结局的比例获胜分数回归模型。
Biometrics. 2021 Dec;77(4):1265-1275. doi: 10.1111/biom.13382. Epub 2020 Oct 10.
6
The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.逆概率删失加权（IPCW）调整后的赢率统计量：在独立删失存在下的无偏估计量。
J Biopharm Stat. 2020 Sep 2;30(5):882-899. doi: 10.1080/10543406.2020.1757692. Epub 2020 Jun 17.
7
Choosing primary endpoints for clinical trials of health care interventions.选择医疗保健干预措施临床试验的主要终点。
Contemp Clin Trials Commun. 2019 Nov 12;16:100486. doi: 10.1016/j.conctc.2019.100486. eCollection 2019 Dec.
本文引用的文献
1
The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial.分析复合结局的胜率方法：在EVOLVE试验中的应用。
Contemp Clin Trials. 2016 May;48:119-24. doi: 10.1016/j.cct.2016.04.001. Epub 2016 Apr 11.
2
A win ratio approach to comparing continuous non-normal outcomes in clinical trials.一种用于比较临床试验中连续非正态结果的胜率方法。
Pharm Stat. 2016 May;15(3):238-45. doi: 10.1002/pst.1743. Epub 2016 Mar 11.
3
Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.基于优先排序组件的复合结局胜率分析的大样本推断
Biostatistics. 2016 Jan;17(1):178-87. doi: 10.1093/biostatistics/kxv032. Epub 2015 Sep 8.
4
Rethinking composite end points in clinical trials: insights from patients and trialists.重新思考临床试验中的复合终点：来自患者和试验人员的见解。
Circulation. 2014 Oct 7;130(15):1254-61. doi: 10.1161/CIRCULATIONAHA.113.006588. Epub 2014 Sep 8.
5
An alternative approach to confidence interval estimation for the win ratio statistic.胜率统计量置信区间估计的另一种方法。
Biometrics. 2015 Mar;71(1):139-145. doi: 10.1111/biom.12225. Epub 2014 Aug 25.
6
Rivaroxaban in patients with a recent acute coronary syndrome.利伐沙班用于近期急性冠状动脉综合征患者。
N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.
7
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.胜率：一种基于临床重点的临床试验中综合终点分析的新方法。
Eur Heart J. 2012 Jan;33(2):176-82. doi: 10.1093/eurheartj/ehr352. Epub 2011 Sep 6.
8
Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.两样本问题中优先结局的广义成对比较。
Stat Med. 2010 Dec 30;29(30):3245-57. doi: 10.1002/sim.3923.
9
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.稳定型冠状动脉疾病中的血管紧张素转换酶抑制作用
N Engl J Med. 2004 Nov 11;351(20):2058-68. doi: 10.1056/NEJMoa042739. Epub 2004 Nov 7.
Zotero 插件